Kinase inhibitors: Adverse effects related to the endocrine system

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages 1333-1342

  Lodish, Maya B ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BOSUTINIB; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; LEVOTHYROXINE; MONOCLONAL ANTIBODY; NILOTINIB; PAMIDRONIC ACID; PANITUMUMAB; PAZOPANIB; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; RUXOLITINIB; SMALL MOLECULE PHOSPHOTRANSFERASE INHIBITOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VEMURAFENIB; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENAL DISEASE; ADRENAL INSUFFICIENCY; BONE DENSITY; BONE DISEASE; BONE MARROW SUPPRESSION; BONE TURNOVER; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; CELL LEVEL; CHILD DEVELOPMENT; CHILD GROWTH; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIARRHEA; DISEASE ACTIVITY; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ENDOCRINE GROWTH AND DEVELOPMENT DISORDERS; ENDOCRINE SYSTEM; ENZYME REGULATION; EOSINOPHILIC LEUKEMIA; FATIGUE; FETUS DEVELOPMENT; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GONAD DYSFUNCTION; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; GYNECOMASTIA; HEAD AND NECK CANCER; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOTHYROIDISM; INTRACELLULAR SIGNALING; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; METASTATIC MELANOMA; MYELOFIBROSIS; NONHUMAN; OVARY INSUFFICIENCY; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COUNSELING; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; SOFT TISSUE SARCOMA; STOMACH CANCER; TERATOGENICITY; THYROID DISEASE; THYROID DYSGENESIS; THYROID FUNCTION; THYROID FUNCTION TEST; THYROID MEDULLARY CARCINOMA; THYROIDITIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT OUTCOME; TUMOR CELL; TUMOR VASCULARIZATION; VITAMIN BLOOD LEVEL; WOUND HEALING; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG TOXICITY; EVALUATION; FEMALE; FERTILITY; JAW DISEASE; PHYSIOLOGY; PREGNANCY; THYROID GLAND;

ANTINEOPLASTIC AGENTS; DRUG TOXICITY; ENDOCRINE SYSTEM; ENDOCRINE SYSTEM DISEASES; FEMALE; FERTILITY; HUMANS; JAW DISEASES; OSTEONECROSIS; PREGNANCY; PROTEIN KINASE INHIBITORS; THYROID GLAND;

MLCS; MLOWN;

EID: 84876223032     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-4085     Document Type: Review

References (116)

1. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172-187.
2. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211-225.
3. Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012;18:2056-2065.
4. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibitionin melanoma with BRAF V600 mutations. N Engl JMed. 2012;367:1694-1703.
5. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
6. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28-39.
7. Daub H. Kinase inhibitors: narrowing down the real targets. Nat Chem Biol. 2010;6:249-250.
8. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127-132.
9. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinaseinhibitors. Nat Biotechnol. 2005;23:329-336.
10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
11. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
12. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory meta-static colorectal cancer. J Clin Oncol. 2007;25:1658-1664.
13. Slamon DJ, Leyland-Jones B, Shak S, et al. Use ofchemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
14. Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist. 2007;12:1443-1455.
15. Lodish MB, Stratakis CA. Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer. 2010;17:R233-R244.
16. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009;6:219-228.
17. Vetter ML, Kaul S, Iqbal N. Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target. Endocr Pract. 2008;14:618-624.
18. Brown RL. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management. Target Oncol. 2011;6:217-226.
19. Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst. 2011;103:1572-1587.
20. Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23:713-722.
21. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther. 2005;78:433-438.
22. Abdulrahman RM, Verloop H, Hoftijzer H, et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab. 2010;95:3758-3762.
23. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714-4719.
24. Dora JM, Leie MA, Netto B, et al. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. Eur J Endocrinol. 2008;158:771-772.
25. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30: 134-141.
26. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145:660-664.
27. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99:448-454.
28. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17:351-355.
29. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81-83.
30. Tamaskar I, Bukowski R, Elson P, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol. 2008;19:265-268.
31. Kim TD, Schwarz M, Nogai H, et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 2010;20: 1209-1214.
32. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931-1939.
33. Schoeffski P, Wolter P, Himpe U, et al. Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation. In: Proceedings from the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, GA. Abstract 3092.
34. Martorella AJ, Omry G, Hann LE, Motzer RJ, Robbins RJ. Receptor kinase (RTK) inhibitor SU11248 may cause hypothyroidism in a select group of patients with metastatic renal cell carcinoma (RCC). In: Proceedings from the 88th Annual Meeting of The Endocrine Society; June 24-27, 2006; Boston, MA. Abstract 593.
35. Shaheen PE, Tamaskar IR, Salas RN, et al. 2006 Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. In: Proceedings from the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, GA. Abstract 4605.
36. Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92:3531-3534.
37. Novartis Pharmaceuticals Corporation. Gleevac (imatinib mesylate): highlights of prescribing information. http://www.pharma.us.novartis.com/ product/pi/pdf/gleevec-tabs.pdf. Updated January 2012. Accessed December 3, 2012.
38. Pfizer Pharmaceuticals Corporation. Sutent (sunitinib malate): highlights of prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx?id= 607. Updated April 2012. Accessed December 3, 2012.
39. Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Schoffski P. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid. 2010;20:317-322.
40. Makita N, Miyakawa M, Fujita T, Iiri T. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid. 2010;20: 323-326.
41. Braun D, Kim TD, le Coutre P, Kohrle J, Hershman JM, Schweizer U. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab. 2012;97: E100-E105.
42. Osorio S, Noblejas AG, Duran A, Steegmann JL. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol. 2007;82:394-395.
43. Grey A, O'Sullivan S, Reid IR, Browett P. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med. 2006;355:2494-2495.
44. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006-2013.
45. Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood.2008;111:2538-2547.
46. Baldazzi V, Tassi R, Lapini A, et al. Sunitinib-induced hyperparathyroidism: a possible mechanism toaltered bone homeostasis. Cancer. 2012;118:3165-3172.
47. Brassard M, Neraud B, Trabado S, et al. Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol Metab. 2011;96:2741-2749.
48. O'Sullivan S, Lin JM, Watson M, et al. The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone. 2011;49:281-289.
49. Joensuu H, Reichardt P. Imatinib and altered bone and mineral metabolism. N Engl J Med. 2006;355:628; author reply 628-629.
50. Owen S, Hatfield A, Letvak L. Imatinib and altered bone and mineral metabolism. N Engl J Med. 2006;355:627; author reply 628-629.
51. Tournis S, Lyritis GP. Imatinib and altered bone and mineral metabolism. N Engl J Med. 2006;355:627; author reply 628-629.
52. Jonsson S, Olsson B, Ohlsson C, Lorentzon M, Mellstrom D, Wadenvik H. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica. 2008;93:1101-1103.
53. O'Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab. 2009;94:1131-1136.
54. Jonsson S, Standal T, Olsson B, Mellstrom D, Wadenvik H. Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib. Am J Hematol. 2012;87:550-552.
55. Vandyke K, Dewar AL, Diamond P, et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res. 2010;25:1759-1770.
56. Id Boufker H, Lagneaux L, Najar M, et al. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer. 2010;10:298.
57. Campone M, Bondarenko I, Brincat S, et al. Phase II study of singleagent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol. 2012;23:610-617.
58. Araujo JC, Mathew P, Armstrong AJ, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012;118:63-71.
59. Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110: 463-469.
60. Agrillo A, Nastro Siniscalchi E, Facchini A, Filiaci F, Ungari C. Osteonecrosis of the jaws inpatients assuming bisphosphonates and sunitinib: two case reports. Eur Rev Med Pharmacol Sci. 2012;16: 952-957.
61. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle GIII, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008;26:4037-4038.
62. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol. 2008;19:2091-2092.
63. Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology. 2009;76:209-211.
64. Ngamphaiboon N, Frustino JL, Kossoff EB, Sullivan MA, O'Connor TL. Osteonecrosis of the jaw: dental outcomes in meta-static breast cancer patients treated with bisphosphonates with/without bevacizumab. Clin Breast Cancer. 2011;11:252-257.
65. McArthur HL, Estilo C, Huryn J, et al. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). In: Proceedings from the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL. Abstract 9588.
66. Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122:181-188.
67. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999; 5:623-628.
68. Vandyke K, Dewar AL, Fitter S, et al. Imatinib mesylate causes growth plate closure in vivo. Leukemia. 2009;23:2155-2159.
69. Suttorp M, Boehme J, Vaitl J, Mosch B, Pursche S, Jung R. Side effects on the heart and skeleton of growing mice attributed to chronic imatinib exposure. In: Proceedings from the American Society of Hematology Annual Meeting; December 6-9, 2008; San Francisco, CA. Abstract 1100.
70. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol. 2009;89:251-252.
71. Mariani S, Giona F, Basciani S, Brama M, Gnessi L. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet. 2008;372:111-112.
72. Schmid H, Jaeger BA, Lohse J, Suttorp M. Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica. 2009;94:1177-1179.
73. Hobernicht SL, Schweiger B, Zeitler P, Wang M, Hunger SP. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. Pediatr Blood Cancer. 2011;56:671-673.
74. Bansal D, Shava U, Varma N, Trehan A, Marwaha RK. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer. 2012;59:481-484.
75. Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr. 2011;159:676-681.
76. Millot F, Baruchel A, Guilhot J, et al. Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia (CML) in early chronic phase (CP): results of the French National Phase IV Trial. In: Proceedings from the American Society of Hematology Annual Meeting; December 5-9, 2009; New Orleans, LA. Abstract 863.
77. Hall AP, Westwood FR, Wadsworth PF. Review of the effects of anti-angiogenic compoundsonthe epiphyseal growth plate. Toxicol Pathol. 2006;34:131-147.
78. Kebapcilar L, Bilgir O, Alacacioglu I, et al. Does imatinib mesylate therapy cause growth hormone deficiency? Med Princ Pract. 2009; 18:360-363.
79. Perry JK, Emerald BS, Mertani HC, Lobie PE. The oncogenic potential of growth hormone. Growth Horm IGF Res. 2006;16:277-289.
80. Tanriverdi O, Unubol M, Taskin F, et al. Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: a literature review. J Oncol Pharm Pract. 2012;18:303-310.
81. Caocci G, Atzeni S, Orru N, et al. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Leukemia. 2008; 22:2127-2128.
82. Ballardini P, Margutti G, Aliberti C, Manfredini R. Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma. Clin Drug Investig. 2009;29:487-490.
83. Kim H, Chang HM, Ryu MH, et al. Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor. J Korean Med Sci. 2005;20:512-515.
84. Gambacorti-Passerini C, Tornaghi L, Cavagnini F, et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet. 2003;361:1954-1956.
85. Basciani S, Mariani S, Arizzi M, et al. Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-α and -β during human testicular development and disease. J Clin Endocrinol Metab. 2002;87:2310-2319.
86. Hoch RV, Soriano P. Roles of PDGF in animal development. Development. 2003;130:4769-4784.
87. Genetech Corporation. Avastatin (bevacizumab): highlights of prescribing information. http://www.gene.com/gene/products/information/pdf/avastin- prescribing.pdf Updated October 2012. Accessed December 3, 2012.
88. Mariani S, Basciani S, Fabbri A, et al. Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertil Steril. 2011;95: 1120.e15-e17.
89. Christopoulos C, Dimakopoulou V, Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med. 2008; 358:1079-1080.
90. Zamah AM, Mauro MJ, Druker BJ, et al. Will imatinib compromise reproductive capacity? Oncologist. 2011;16:1422-1427.
91. Schultheis B, Nijmeijer BA, Yin H, Gosden RG, Melo JV. Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res. 2012;36: 271-274.
92. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol. 2003;40(2 suppl 2):21-25.
93. Ault P, Kantarjian H, O'Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006;24:1204-1208.
94. Ramasamy K, Hayden J, Lim Z, Mufti GJ, Ho AY. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol. 2007;137:374-375.
95. Breccia M, Cannella L, Montefusco E, Frustaci A, Pacilli M, Alimena G. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res. 2008;32:519-520.
96. Apperley J. Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw. 2009;7:1050-1058.
97. Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505-5508.
98. Soriano P. The PDGF α receptor is required for neural crest cell development and for normal patterning of the somites. Development. 1997;124:2691-2700.
99. Azim HA Jr, Metzger-Filho O, de Azambuja E, et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat. 2012;133:387-391.
100. Azim HA Jr, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol. 2010;6:821-826.
101. Gavi S, Shumay E, Wang HY, Malbon CC. G-Protein-coupled receptors and tyrosine kinases: crossroads in cell signaling and regulation. Trends Endocrinol Metab. 2006;17:48-54.
102. Robinson AA, Watson WJ, Leslie KK. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Oncol. 2007;8:738-743.
103. Gucalp A, Sparano JA, Caravelli J, et al. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer. 2011;11:306-311.
104. Bilgir O, Kebapcilar L, Bilgir F, et al. Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction? Int J Clin Pract. 2010;64:45-50.
105. Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12:107-113.
106. Billemont B, Medioni J, Taillade L, et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer. 2008;99:1380-1382.
107. Veneri D, Franchini M, Bonora E. Imatinib and regression of type 2 diabetes. N Engl J Med. 2005;352:1049-1050.
108. Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol. 2004;22:4653-4655.
109. Breccia M, Muscaritoli M, Cannella L, Stefanizzi C, Frustaci A, Alimena G. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res. 2008;32:1626-1628.
110. Templeton A, Brandle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol. 2008;19:824-825.
111. Hamberg P, de Jong FA, Boonstra JG, van Doorn J, Verweij J, Sleijfer S. Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol. 2006;24:e30-e31.
112. Lee Y, Jung HS, Choi HJ, et al. Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: a case report. Diabetes Res Clin Pract. 2011;93: e68-e70.
113. Haap M, Gallwitz B, Thamer C, et al. Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor. J Endocrinol Invest. 2007;30: 688-692.
114. Agostino NM, Chinchilli VM, Lynch CJ, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract. 2011;17:197-202.
115. Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008;30:1956-1975.
116. Saglio G, Larson RA, Hughes TP, et al. Efficacy and safety of nilotinib in chronic phase (CP) chrome myeloid leukemia (CML) patients (Pts) with type 2 diabetes in the ENESTnd Trial. In: Proceedings from the American Society of Hematology Annual Meeting; December 4-7, 2010; Orlando, FL. Abstract 3430.